NEW ANTIMICROBIALS IN THE CURRENT PIPELINE ACTIVE AGAINST MULTIDRUG-RESISTANT BACTERIA
Keywords:
new antimicrobials, antibiotic resistance, multidrug-resistant bacteriaAbstract
For seven decades, humanity has benefited from the availability of antibiotics to treat bacterial
infections.
However, the overuse of antibiotics puts pressure on bacteria to develop resistance to these drugs, leading to the
emergence of untreatable "superbugs". Over the past few decades, antibiotic resistance in particular, multidrug
resistance has risen to dangerously high levels worldwide and is becoming a critical global health issue.
Nevertheless, the development of new antibacterial treatments does not seem to be adequate to address the growing
threat of antibiotic resistance. Purpose: To review the new antimicrobials in the current pipeline active against
multidrug-resistant bacteria. Methodology: systematic review and analysis of scientific literature. Results: Show a
summary of the reviewed antibiotics in the pipeline and their spectrum of activities. Conclusions: Multidrugresistant
bacteria are a serious threat to public health, an outstanding challenge for therapeutic models. Further
research, development and validation of rapid and reliable diagnostic techniques to identify resistance patterns are
urgently needed to select best approaches and practices for the prevention and control of MDR infections. To ensure
that the supply of new antibiotics keeps pace with these evolving pathogens, it is necessary to have a robust pipeline
of new drugs—as well as innovative pathways to bring this medicine to the patients who need it most.
References
Al-Tawfiq, J. A., Momattin, H., Al-Ali, A. Y., Eljaaly, K., Tirupathi, R., Haradwala, M. B., Areti, S., Alhumaid, S., Rabaan, A. A., Al Mutair, A., & Schlagenhauf, P. (2022). Antibiotics in the pipeline: a literature review (2017-2020). Infection, 50(3), 553–564.
Antimicrobial Resistance Global Report on Surveillance, World Health Organization, Geneva, Switzerland, 2014.
Bharadwaj, A., Rastogi, A., Pandey, S., Gupta, S., & Sohal, J. S. (2022). Multidrug-Resistant Bacteria: Their Mechanism of Action and Prophylaxis. BioMed research international, 2022, 5419874.
Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D. L., Rice, L. B., Stelling, J., Struelens, M. J., Vatopoulos, A., Weber, J. T., & Monnet, D. L. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(3), 268–281.
Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug resistant
bacterial infections, including tuberculosis. Geneva: World Health Organization; 2017. https://www.who.int/medicines/areas/rational_use/ prioritization-of-pathogens/en/
Singh V. “Antimicrobial resistance” in Microbial Pathogens and Strategies for Combating Them. Science,
Technology and Education. 2013/1:291–296
Tanwar, J., Das, S., Fatima, Z., & Hameed, S. (2014). Multidrug resistance: an emerging crisis. Interdisciplinary perspectives on infectious diseases, 2014, 541340. https://doi.org/10.1155/2014/541340
Terreni, M., Taccani, M., & Pregnolato, M. (2021). New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules (Basel, Switzerland), 26(9), 2671.
https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
AWaRe classification. Geneva: World Health Organization; 2021
Antibacterial agents in clinical and preclinical development: an overview and analysis.
Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
